Nachman Norwood & Parrott’s Quince Therapeutics QNCX Stock Holding History

Nachman Norwood & Parrott’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$292K	Buy	+28	New	+$235K	0.03%	240

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Nachman Norwood & Parrott's QNCX Position: Q2 2021 in Review

Nachman Norwood & Parrott opened a new position in Quince Therapeutics (QNCX) in Q2 2021: 28 shares worth $292K. The stake represents 0.03% of the portfolio and ranks #240 among its holdings.

100 funds tracked by Wall St. Rank hold QNCX as of Q2 2021.

Nachman Norwood & Parrott held 28 shares of Quince Therapeutics worth $292K as of Q2 2021.
Quince Therapeutics was a new Nachman Norwood & Parrott position in Q2 2021.
Quince Therapeutics made up 0.03% of Nachman Norwood & Parrott's portfolio in Q2 2021, its #240 holding.
100 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2021.

Based on Nachman Norwood & Parrott's 13F filing for Q2 2021, filed 13 Aug 2021.